These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9816275)

  • 21. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
    Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Redei I; Green F; Hoffman JP; Weiner LM; Scher R; O'Dwyer PJ
    Invest New Drugs; 1994; 12(4):319-21. PubMed ID: 7775133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
    Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
    Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
    J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ
    Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
    Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
    Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
    Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
    Casper ES; Baselga J; Smart TB; Magill GB; Markman M; Ranhosky A
    Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
    Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
    Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ; Powis G; Rubin J; Moertel CG
    Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
    Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
    Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid.
    Budd GT; Jayaraj A; Grabowski D; Adelstein D; Bauer L; Boyett J; Bukowski R; Murthy S; Weick J
    Cancer Res; 1990 Nov; 50(22):7206-11. PubMed ID: 2224854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
    Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
    Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.